Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2009 1
2010 1
2011 3
2012 1
2013 1
2014 5
2015 2
2016 3
2017 7
2018 4
2019 5
2020 4
2021 5
2022 8
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass.
Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S. Bonnet N, et al. J Clin Invest. 2019 May 23;129(8):3214-3223. doi: 10.1172/JCI125915. J Clin Invest. 2019. PMID: 31120440 Free PMC article.
Receptor activator of Nfkb ligand (RANKL) activates, while osteoprotegerin (OPG) inhibits, osteoclastogenesis. ...We investigated the effects of RANKL inhibitors on muscle in osteoporotic women and mice that either overexpress RANKL (HuRANKL-Tg+), or lack Ppa …
Receptor activator of Nfkb ligand (RANKL) activates, while osteoprotegerin (OPG) inhibits, osteoclastogenesis. ...We investigated the …
Osteocyte necrosis triggers osteoclast-mediated bone loss through macrophage-inducible C-type lectin.
Andreev D, Liu M, Weidner D, Kachler K, Faas M, Grüneboom A, Schlötzer-Schrehardt U, Muñoz LE, Steffen U, Grötsch B, Killy B, Krönke G, Luebke AM, Niemeier A, Wehrhan F, Lang R, Schett G, Bozec A. Andreev D, et al. J Clin Invest. 2020 Sep 1;130(9):4811-4830. doi: 10.1172/JCI134214. J Clin Invest. 2020. PMID: 32773408 Free PMC article.
Although the control of bone-resorbing osteoclasts through osteocyte-derived RANKL is well defined, little is known about the regulation of osteoclasts by osteocyte death. ...
Although the control of bone-resorbing osteoclasts through osteocyte-derived RANKL is well defined, little is known about the regulat …
ETS1 governs pathological tissue-remodeling programs in disease-associated fibroblasts.
Yan M, Komatsu N, Muro R, Huynh NC, Tomofuji Y, Okada Y, Suzuki HI, Takaba H, Kitazawa R, Kitazawa S, Pluemsakunthai W, Mitsui Y, Satoh T, Okamura T, Nitta T, Im SH, Kim CJ, Kollias G, Tanaka S, Okamoto K, Tsukasaki M, Takayanagi H. Yan M, et al. Nat Immunol. 2022 Sep;23(9):1330-1341. doi: 10.1038/s41590-022-01285-0. Epub 2022 Aug 23. Nat Immunol. 2022. PMID: 35999392
In arthritis, ETS1 drives polarization toward tissue-destructive fibroblasts by orchestrating hitherto undescribed regulatory elements of the osteoclast differentiation factor receptor activator of nuclear factor-kappaB ligand (RANKL) as well as matrix metalloproteinases. …
In arthritis, ETS1 drives polarization toward tissue-destructive fibroblasts by orchestrating hitherto undescribed regulatory elements of th …
RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy.
Ndip A, Wilkinson FL, Jude EB, Boulton AJ, Alexander MY. Ndip A, et al. Diabetologia. 2014 Nov;57(11):2251-60. doi: 10.1007/s00125-014-3348-z. Epub 2014 Aug 12. Diabetologia. 2014. PMID: 25112376 Review.
An emerging regulatory pathway for vascular calcification in diabetes involves the receptor activator for nuclear factor kappaB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG). Important novel biomarkers of calcification are related to levels of glycation and inflamm …
An emerging regulatory pathway for vascular calcification in diabetes involves the receptor activator for nuclear factor kappaB (RANK), RANK …
Bona fide dendritic cells are pivotal precursors for osteoclasts.
Puchner A, Simader E, Saferding V, Hofmann M, Kieler M, Brunner J, Pfeifle R, Niederreiter B, Krönke G, Schabbauer G, Georgel P, Diehl G, Steiner G, Hayer S, Redlich K, Smolen JS, Aletaha D, Blüml S. Puchner A, et al. Ann Rheum Dis. 2024 Mar 12;83(4):518-528. doi: 10.1136/ard-2022-223817. Ann Rheum Dis. 2024. PMID: 38071515
We sorted murine and human OC precursors and stimulated them with macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL) to generate OCs. RESULTS: Targeting CD11c(+) cells in vivo in models of inflammatory arthritis (ST …
We sorted murine and human OC precursors and stimulated them with macrophage colony-stimulating factor (M-CSF) and receptor activator of nuc …
New Insights for RANKL as a Proinflammatory Modulator in Modeled Inflammatory Arthritis.
Papadaki M, Rinotas V, Violitzi F, Thireou T, Panayotou G, Samiotaki M, Douni E. Papadaki M, et al. Front Immunol. 2019 Feb 5;10:97. doi: 10.3389/fimmu.2019.00097. eCollection 2019. Front Immunol. 2019. PMID: 30804932 Free PMC article.
Here, we used the human TNF transgenic mouse model of erosive inflammatory arthritis to determine if the progression of inflammation is affected by either genetic inactivation or overexpression of RANKL in transgenic mouse models. TNF-mediated inflammatory arthritis was si …
Here, we used the human TNF transgenic mouse model of erosive inflammatory arthritis to determine if the progression of inflammation is affe …
Current Status and Future Prospects of Small-molecule Protein-protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-kappaB Ligand (RANKL).
Melagraki G, Leonis G, Ntougkos E, Rinotas V, Papaneophytou C, Mavromoustakos T, Kontopidis G, Douni E, Kollias G, Afantitis A. Melagraki G, et al. Curr Top Med Chem. 2018;18(8):661-673. doi: 10.2174/1568026618666180607084430. Curr Top Med Chem. 2018. PMID: 29875003 Review.
The function of RANKL is physiologically inhibited by the action of osteoprotegerin (OPG), which is a decoy receptor that binds to RANKL and prevents the process of osteoclastogenesis. ...To disrupt the unwanted functions of TNF and RANKL, current attempts fo …
The function of RANKL is physiologically inhibited by the action of osteoprotegerin (OPG), which is a decoy receptor that binds to …
RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women.
Wunderle M, Ruebner M, Häberle L, Schwenke E, Hack CC, Bayer CM, Koch MC, Schwitulla J, Schulz-Wendtland R, Kozieradzki I, Lux MP, Beckmann MW, Jud SM, Penninger JM, Schneider MO, Fasching PA. Wunderle M, et al. Sci Rep. 2020 Mar 20;10(1):5171. doi: 10.1038/s41598-020-62070-3. Sci Rep. 2020. PMID: 32198488 Free PMC article.
A linear regression model including breast volume at the start of pregnancy, RANKL, OPG, and other factors was used to predict breast volume at term. ...Linking the RANKL/RANK/OPG pathway with breast volume changes supports further studies aiming at analysing breast …
A linear regression model including breast volume at the start of pregnancy, RANKL, OPG, and other factors was used to predict breast …
53 results